Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Rhea-AI Summary
Eton Pharmaceuticals (NASDAQ: ETON) will report first quarter 2026 financial results on Thursday, May 14, 2026, and will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT).
Management will take live questions on the call and answer emailed investor questions sent to investorrelations@etonpharma.com. The live webcast is available on the company's Investors website, with an archived webcast posted about two hours after the event and available for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ETON
In the May 5 session, ETON gained 0.73%, reflecting a mild positive market reaction. Argus tracked a peak move of +7.2% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Earnings date notice | Neutral | +0.5% | Scheduled Q4 and full-year 2025 results with post-close conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date scheduling news produced a small positive move, suggesting such notices have historically had limited direct price impact.
Recent news shows Eton executing on multiple fronts. In March 2026, it pre‑announced its Q4 and full‑year 2025 earnings date, which saw only a 0.46% move, followed by strong reported results and guidance. The company then expanded its rare disease portfolio through the HEMANGEOL acquisition and advanced ET‑700 into clinical study. Against this backdrop, today’s first‑quarter 2026 earnings date notice fits an ongoing cadence of operational and financial updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Participant Call Link: | Click Here |
| Webcast: | Click Here |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVITM, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
